

This Offering Document (the “**Offering Document**”) constitutes an offering of these securities only in those jurisdictions where they may be lawfully offered for sale and therein only by persons permitted to sell such securities and to those persons to whom they may be lawfully offered for sale. This Offering Document is not, and under no circumstances is to be construed as a prospectus or advertisement or a public offering of these securities.

These securities have not been registered under the United States Securities Act of 1933, as amended (the “**U.S. Securities Act**”), or any of the securities laws of any state of the United States, and may not be offered or sold within the United States or for the account or benefit of U.S. persons or persons in the United States except pursuant to an exemption from the registration requirements of the U.S. Securities Act and applicable U.S. state securities laws. This Offering Document does not constitute an offer to sell, or the solicitation of an offer to buy, any of these securities within the United States or to, or for the account or benefit of, U.S. persons or persons in the United States. “**United States**” and “**U.S. person**” have the meanings ascribed to them in Regulation S under the U.S. Securities Act.

OFFERING DOCUMENT UNDER THE LISTED ISSUER FINANCING EXEMPTION

August 17, 2023

TREATMENT.COM INTERNATIONAL INC. (the “**Issuer**”, “**Treatment**” or “**we**”)

SUBSCRIPTION PRICE: \$0.10 PER COMMON SHARE

What are we offering?

Offering:	Common shares in the capital of the Issuer (each, a “ Common Share ”).
Offering Price:	\$0.10 per Common Share.
Offering Amount:	A minimum of 10,000,000 Common Shares, for gross proceeds of up to \$1,000,000 (the “ Offering ”). Closing of the Offering is subject to the Issuer completing the Debt Settlement (as defined herein).
Debt Settlement	In addition to the Offering, the Issuer intends to settle up to \$1,800,000 of the Issuer’s liabilities at a price of \$0.10 per Common Share (the “ Debt Settlement ”). Closing of the Offering is conditional upon the Company completing the Debt Settlement and obtaining shareholders’ approval.
Closing Date:	The closing of the Offering may take place in one or more tranches, the first of which is expected to close on or about September 18, 2023.
Exchange:	The Common Shares are listed on the Canadian Securities Exchange (the “ CSE ”), under the symbol “ TRUE ”.
Last Closing Price:	The closing price of the Common Shares on the CSE on August 16, 2023 was \$0.22.

Description of Common Shares

The holders of the Common Shares are entitled to dividends, if, as and when declared by the Board of Directors, to receive notice of meetings of shareholders of the Company, to one vote per Common Share at meetings of the shareholders of the Company and, upon liquidation, to receive such assets of the Company as are distributable to the holders of the Common Shares. Holders of Common Shares do not have cumulative voting rights with respect to the election of directors and, accordingly, holders of a majority of the votes eligible to vote at a meeting of shareholders may elect all the directors of the Company standing for election. Dividends, if any, will be paid on a pro rata basis only from funds legally

available therefore. The Common Shares do not carry any pre-emptive, subscription, redemption or conversion rights, nor do they contain any sinking or purchase fund provisions.

No securities regulatory authority or regulator has assessed the merits of these securities or reviewed this document. Any representation to the contrary is an offence. This offering may not be suitable for you and you should only invest in it if you are willing to risk the loss of your entire investment. In making this investment decision, you should seek the advice of a registered dealer.

The Issuer is conducting a listed issuer financing under section 5A.2 of National Instrument 45-106 Prospectus Exemptions. In connection with this offering, the Issuer represents the following is true:

- **The Issuer has active operations and its principal asset is not cash, cash equivalents or its exchange listing.**
- **The Issuer has filed all periodic and timely disclosure documents that it is required to have filed.**
- **The total dollar amount of this Offering, in combination with the dollar amount of all other offerings made under the listed issuer financing exemption in the 12 months immediately before the date of this offering document, will not exceed \$5,000,000.**
- **The Issuer will not close this Offering unless the Issuer reasonably believes it has raised sufficient funds to meet its business objectives and liquidity requirements for a period of 12 months following the distribution.**
- **The Issuer will not allocate the available funds from this Offering to an acquisition that is a significant acquisition or restructuring transaction under securities law or to any other transaction for which the Issuer seeks security holder approval.**

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

Certain statements in this Offering Document are forward-looking statements or information (collectively “**forward-looking statements**”). Treatment is hereby providing cautionary statements identifying important factors that could cause the actual results of Treatment to differ materially from those projected in the forward-looking statements. Any statements that express, or involve discussions as to, expectations, beliefs, plans, objectives, assumptions or future events or performance (often, but not always, through the use of words or phrases such as “may”, “is expected to”, “anticipates”, “estimates”, “intends”, “plans”, “projection”, “could”, “vision”, “goals”, “objective” and “outlook”) are not historical facts and may be forward-looking and may involve estimates, assumptions and uncertainties, which could cause actual results or outcomes to differ materially from those expressed in the forward-looking statements. In particular, forward-looking statements in this Offering Document include, but are not limited to, statements about:

- performance of the Issuer’s products and product candidates;
- supply and demand of the Issuer’s products;
- projections on revenues generated from the sale of the Issuer’s products (or related products);
- regulatory approval and market acceptance of the Issuer’s products;
- growth strategy and opportunities;
- anticipated operating expenses and business operational requirements;
- future funds from operations;
- expectations regarding the ability to raise capital; and

- the proposed use of proceeds of the Offering and available funds.

All forward-looking statements, including, without limitation, our examination of historical operating trends, are based upon our current expectations and various assumptions. Certain assumptions made in preparing the forward-looking statements include:

- the ongoing ability of the Issuer to develop, manufacture and market its products;
- the availability of capital to undertake planned expenditures;
- the ability of the Issuer to attract wholesale and retail customers;
- the ability of the Issuer to obtain regulatory approval for its products;
- the market for the Issuer's products will continue to grow;
- the availability and cost of labour and services; and
- prevailing applicable laws remaining unchanged.

We believe there is a reasonable basis for our expectations and beliefs, but they are inherently uncertain. We may not realize our expectations, and our beliefs may not prove correct. Actual results could differ materially from those described or implied by such forward-looking statements. The following uncertainties and factors, among others, could affect future performance and cause actual results to differ materially from those matters expressed in or implied by forward-looking statements: the ability of the Issuer to leverage its technology to offer new solutions; ability of the Issuer to compete with both direct and indirect competition; the ability of the Issuer to prevent third parties from using its intellectual property; reliance on physicians and other healthcare professionals; infrastructure risks; cybersecurity risks; the ability of the Issuer to address the privacy concerns of existing and future clients; changes in government regulation, delisting of services, and licensing requirements relating to healthcare services, or their interpretation and application; ability of the Issuer to respond to technological advances in its industry; the ability of the Issuer to estimate and forecast market opportunity and growth; the ability of the Issuer to attract new customers and generate sales; reputational risks; litigation risks; conflicts of interest; the ability of the Issuer to develop and maintain effective internal controls; no cash dividends in the foreseeable future; global financial conditions; public health crises; dependence on the Issuer's management team to operate the business; limited operating results; ability of the Issuer to implement its business plan, raise capital and generate revenues; lack of working capital; proceeds from any future financings may be used to fund any negative cash flow from operating activities; the ability of the Issuer to manage growth; incurrence of significant ongoing costs and obligations related to the Issuer's investment in infrastructure, growth, regulatory compliance and operations; foreign currency risk; ability of the Issuer to comply with securities laws; no market for the Common Shares; illiquidity and price volatility of the Common Shares; and potential political risks on the Issuer's business.

Further, any forward-looking statement speaks only as of the date on which such statement is made, and, except as required by applicable law, the Issuer undertakes no obligation to update any forward-looking statement to reflect events or circumstances after the date on which such statement is made or to reflect the occurrence of unanticipated events. New factors emerge from time to time, and it is not possible for management to predict all such factors and to assess in advance the impact of each such factor on the business of Treatment or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statement.

1 SUMMARY DESCRIPTION OF BUSINESS

What Is Our Business?

Treatment is an artificial intelligence company based in Vancouver, British Columbia that supports business-to-business access to intelligent, personalized, diagnostic and treatment resources for healthcare organizations and medical professionals. Based on a neural network of high quality, validated, and tested medical knowledge on over 1,000 diagnoses and tens of thousands of symptoms, physical exam findings, laboratory and radiologic tests, and risk factors, the company provides access to a Global Library of Medicine (GLM). The AI engine supporting the GLM speeds the integration of AI enhanced medical capabilities into new or existing software. Access to the library is provided by APIs licensed directly from the company or by functional modules licensed through a Palo Alto API marketplace. The library delivers age, sex, and location specific information, enhanced conversational interfaces through LLM integration, and continual improvement through machine learning.

Recent Developments

On June 30, 2023, the Issuer announced its Board of Directors approved a consolidation of all of the Issuer's issued and outstanding Common Shares on the basis of ten (10) pre-consolidated Common Shares for every one (1) post-consolidated Common Share (the "**Consolidation**"). The Consolidation was made effective July 14, 2023.

Material Facts

None.

What are the business objectives that we expect to accomplish using the available funds?

The Issuer has set the following business objectives and milestones:

Business objectives	Description of preceding significant event(s) (each, an "Event")	Period in which Event is expected to occur	Cost related to Event
Product related costs	Software upgrades and enhancements and testing and maintenance	Q4 2023	\$285,000
Updating and validation of the medical library		Ongoing	\$100,000
Total:			\$385,000

2 USE OF AVAILABLE FUNDS

What will our available funds be upon the closing of the Offering?

		Offering
A	Amounts to be raised by the Offering	\$1,000,000
B	Selling commissions and fees	\$70,000

		Offering
C	Estimated Offering costs (e.g., legal, accounting, audit)	\$50,000
D	Net proceeds of Offering: $D = A - (B+C)$	\$880,000
E	Working capital as at July 31, 2023 (deficiency)	\$(2,107,714)
F	Additional sources of funding	\$1,800,000 ⁽¹⁾
G	Total available funds: $G = D+E+F$	\$572,286

Notes:

(1) Assuming the Debt Settlement of \$1,800,000 is completed.

How will we use the available funds?

The Issuer intends to use the available funds as follows:

Description of intended use of available funds listed in order of priority	Assuming Maximum Offering
Product related costs	\$285,000
Continued updating and validation of the medical library	\$100,000
General and administrative expenses	\$150,000
Unallocated working capital	\$37,286
Total:	\$572,286

3 USE OF FUNDS FROM PREVIOUS FINANCINGS

How have we used the other funds we have raised in the past 12 months?

The Issuer has not raised new funds in the past 12 months. Debt incurred by friends and employees of the Issuer was used to continue the Issuer's operations. Financing of this debt was primarily through stock, and was announced prior to this offer. The following table sets out the particulars of how the Issuer used proceeds from debt incurred in the past 12 months, as well as an explanation of the variances, if any, from the Issuer's anticipated use of proceeds as disclosed in documents previously filed with securities commissions or similar authorities in Canada, and the impact of any variances on the Issuer's ability to achieve its business objectives and milestones:

Previous description of intended use of funds	Funds allocated to intended use	Variances	Impact of the variances on Issuer's ability to achieve business objectives
Infrastructure support, including hardware and software expenses	\$96,000	0	Nil
Extension of GLM interfaces and testing	\$10,000	0	Nil

Continued updating and validation of the medical library	\$30,000	0	Nil
Service support for customers	\$4,000	0	Nil
General corporate purposes	\$60,000	0	Nil
Unallocated working capital	\$0	0	Nil

4 FEES AND COMMISSIONS

Who are the dealers or finders that we have engaged in connection with this offering, if any, and what are their fees?

None.

Does dealer(s) have a conflict of interest?

Not applicable.

U.S. OFFERING RESTRICTIONS

The Common Shares have not been and will not be registered under the U.S. Securities Act or the securities laws of any state in the United States and, subject to certain exemptions from registration under the U.S. Securities Act and applicable state securities laws, may not be offered or sold within the United States or to, or for the account or benefit of, U.S. persons or persons in the United States.

This Offering Document does not constitute an offer to sell or a solicitation of an offer to buy any Common Shares in the United States to, or for the account or benefit of, U.S. persons or persons in the United States. In addition, until 40 days after the commencement of the Offering, an offer or sale of Common Shares within the United States or, to or for the account or benefit of, U.S. persons or persons in the United States by any dealer (whether or not participating in the Offering) may violate the registration provisions of the U.S. Securities Act unless made otherwise than in accordance with an exemption from the registration requirements under the U.S. Securities Act and similar exemptions under applicable state securities laws.

5 PURCHASERS' RIGHTS

Rights of action in the Event of a Misrepresentation

If there is a misrepresentation in this offering document, you have a right

- a) to rescind your purchase of these securities with the Issuer, or**
- b) to damages against the Issuer and may, in certain jurisdictions, have a statutory right to damages from other persons.**

These rights are available to you whether or not you relied on the misrepresentation. However, there are various circumstances that limit your rights. In particular, your rights might be limited if you knew of the misrepresentation when you purchased the Securities.

If you intend to rely on the rights described in paragraph (a) or (b) above, you must do so within strict time limitations.

You should refer to any applicable provisions of the securities legislation of your province or territory for the particulars of these rights or consult with a legal adviser.

6 ADDITIONAL INFORMATION

Where can you find more information about us?

You can access the Issuer's continuous disclosure under its profile at www.SEDARplus.ca and at <https://Treatment.com/>.

[Remainder of Page Intentionally Left Blank]

7 **DATE AND CERTIFICATE**

Dated: August 17, 2023

This offering document, together with any document filed under Canadian securities legislation on or after August 17, 2022, contains disclosure of all material facts about the Securities being distributed and does not contain a misrepresentation.

“Kevin Peterson”

Kevin Peterson
Interim Chief Executive Officer

“Dong H. Shim”

Dong H. Shim
Chief Financial Officer